Comment on: Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system

J Antimicrob Chemother. 2011 May;66(5):1193-4; author reply 1194-5. doi: 10.1093/jac/dkr031. Epub 2011 Feb 15.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-Bacterial Agents / administration & dosage*
  • CD4-Positive T-Lymphocytes / immunology
  • Colon / microbiology
  • Crohn Disease / drug therapy*
  • Crohn Disease / immunology
  • Cytokines / metabolism
  • Humans
  • Immunologic Factors / administration & dosage*
  • Lymphocyte Subsets / immunology
  • Metagenome / drug effects*
  • Models, Theoretical
  • Rifamycins / administration & dosage*
  • Rifaximin

Substances

  • Anti-Bacterial Agents
  • Cytokines
  • Immunologic Factors
  • Rifamycins
  • Rifaximin